Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
At a conference largely focused on big biopharma a few biotech catalysts stand out.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
Boehringer Ingelheim buys NBE-Therapeutics, the second Ror1-focused player to be taken out in just over a month.